Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with Standard Care for Newly Presenting TTP
NCT00251277Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2005
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by Weill Cornell Medicine. Primary endpoint: Failure to maintain the complete response until day 120. Planned start Nov 2005; status: withdrawn.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT00251277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251277.